Sanofi Still Bets On Multiple Sclerosis Med Tolebrutinib Despite The Investigational Drug Fell Short In 2 Of 3 Phase 3 Trials. Story by Vandana Singh • 1mo. S unday, ...

Sanofi said an oral treatment for multiple sclerosis, tolebrutinib, met its key goal in a Phase 3 study, potentially clearing the way for regulatory approval, although in two other studies ...

Sanofi’s experimental drug for a form of multiple sclerosis delayed the progression of disability by nearly a third, providing hope for patients for whom there’s currently no treatment.

Sanofi‘s most advanced multiple sclerosis drug candidate failed to achieve the main goal of two late-stage trials to treat relapsing forms of the disease.However, the drug was able to succeed in ...

Sanofi’s multiple sclerosis drug prospects include two proverbial shots on goal. With the first one stalled by a clinical hold, Sanofi is welcoming positive clinical data for a second one, ...

Sanofi has a strong portfolio of multiple sclerosis medicines. However, sales of its key drug, Aubagio, approved for relapsing-remitting multiple sclerosis, are expected to decline as generics ...

Sanofi Multiple Sclerosis Drug Delays Disability Progression in Trial — Update Provided by Dow Jones Sep 2, 2024, 8:29:00 AM. By David Sachs and Adria Calatayud .

Sanofi has stopped a phase 2 trial of Denali Therapeutics-partnered oditrasertib in multiple sclerosis. The French drugmaker tore the RIPK1 inhibitor trial from its list of active studies after it ...

A Sanofi experimental drug for multiple sclerosis delayed disability progression in a late-stage trial, but failed to reduce episodes of new or worsening symptoms compared to an existing treatment ...

Discover results from Sanofi's Phase 2 study on frexalimab for relapsing multiple sclerosis. Explore sustained reduction in disease activity and lesion numbers with low relapse rates.

Sanofi CEO Olivier Brandicourt said Genzyme showed "excellent sales growth this quarter of 27 percent,” mostly due to stellar sales of its multiple sclerosis drug, Aubagio.